Glucose transporter 1-positive endothelial cells in infantile hemangioma exhibit features of facultative stem cells

Stem Cells

Volumn 33, Issue 1, 2015, Pages 133-145

  Huang, Lan ^a,b   Nakayama, Hironao ^a,b   Klagsbrun, Michael ^a,b   Mulliken, John B ^a,b   Bischoff, Joyce ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Endothelial cells; Facultative stem cells; Glucose transporter 1; Infantile hemangioma

Indexed keywords

ANGIOPOIETIN 2; CD31 ANTIGEN; GLUCOSE TRANSPORTER 1; JAGGED1; PROPRANOLOL; RAPAMYCIN; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR 2; SLC2A1 PROTEIN, HUMAN;

ADIPOCYTE; ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CAPILLARY HEMANGIOMA; CELL DIFFERENTIATION; CELL ISOLATION; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INFANT; MOUSE; NONHUMAN; PERICYTE; PHENOTYPE; PREMEDICATION; SMOOTH MUSCLE FIBER; STEM CELL; CANCER STEM CELL; DRUG EFFECTS; FEMALE; HEMANGIOMA; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PRESCHOOL CHILD;

CELL DIFFERENTIATION; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; ENDOTHELIAL CELLS; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HEMANGIOMA; HUMANS; INFANT; MALE; NEOPLASTIC STEM CELLS; PROPRANOLOL; SIROLIMUS; STEM CELLS;

EID: 84919427606     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1841     Document Type: Article

References (57)

1. Enjolras O, Mulliken JB,. The current management of vascular birthmarks. Pediatr Dermatol 1993; 10: 311-313.
2. Frieden IJ, Haggstrom AN, Drolet BA, et al. Infantile hemangiomas: Current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol 2005; 22: 383-406.
3. North PE, Waner M, Mizeracki A, et al. GLUT1: A newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 2000; 31: 11-22.
4. North PE, Waner M, Mizeracki A, et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol 2001; 137: 559-570.
5. Boye E, Yu Y, Paranya G, et al. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest 2001; 107: 745-752.
6. Khan ZA, Melero-Martin JM, Wu X, et al. Endothelial progenitor cells from infantile hemangioma and umbilical cord blood display unique cellular responses to endostatin. Blood 2006; 108: 915-921.
7. Smadja DM, Mulliken JB, Bischoff J,. E-selectin mediates stem cell adhesion and formation of blood vessels in a murine model of infantile hemangioma. Am J Pathol 2012; 181: 2239-2247.
8. Boscolo E, Mulliken JB, Bischoff J,. Pericytes from infantile hemangioma display proangiogenic properties and dysregulated angiopoietin-1. Arterioscler Thromb Vasc Biol 2013; 33: 501-509.
9. Boscolo E, Stewart CL, Greenberger S, et al. JAGGED1 signaling regulates hemangioma stem cell-to-pericyte/vascular smooth muscle cell differentiation. Arterioscler Thromb Vasc Biol 2011; 31: 2181-2192.
10. Khan ZA, Boscolo E, Picard A, et al. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest 2008; 118: 2592-2599.
11. Xu D, O TM, Shartava A, et al. Isolation, characterization, and in vitro propagation of infantile hemangioma stem cells and an in vivo mouse model. J Hematol Oncol 2011; 4: 54.
12. Calicchio ML, Collins T, Kozakewich HP,. Identification of signaling systems in proliferating and involuting phase infantile hemangiomas by genome-wide transcriptional profiling. Am J Pathol 2009; 174: 1638-1649.
13. Kraling BM, Razon MJ, Boon LM, et al. E-selectin is present in proliferating endothelial cells in human hemangiomas. Am J Pathol 1996; 148: 1181-1191.
14. O TM, Tan, M, Tarango, M, et al. Differential expression of SKI oncogene protein in hemangiomas. Otolaryngol Head Neck Surg 2009; 141: 213-218.
15. Yu Y, Varughese J, Brown LF, et al. Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am J Pathol 2001; 159: 2271-2280.
16. Dosanjh A, Chang J, Bresnick S, et al. In vitro characteristics of neonatal hemangioma endothelial cells: Similarities and differences between normal neonatal and fetal endothelial cells. J Cutan Pathol 2000; 27: 441-450.
17. Jinnin M, Medici D, Park L, et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 2008; 14: 1236-1246.
18. Greenberger S, Boscolo E, Adini I, et al. Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. N Engl J Med 2010; 362: 1005-1013.
19. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649-2651.
20. Cheng JF, Gole GA, Sullivan TJ,. Propranolol in the management of periorbital infantile haemangioma. Clin Experiment Ophthalmol 2010; 38: 547-553.
21. Mazereeuw-Hautier J, Hoeger PH, Benlahrech S, et al. Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Pediatr 2010; 157: 340-342.
22. Rosbe KW, Suh KY, Meyer AK, et al. Propranolol in the management of airway infantile hemangiomas. Arch Otolaryngol Head Neck Surg 2010; 136: 658-665.
23. Bagazgoitia L, Hernandez-Martin A, Torrelo A,. Recurrence of infantile hemangiomas treated with propranolol. Pediatr Dermatol 2011; 28: 658-662.
24. Marqueling AL, Oza V, Frieden IJ, et al. Propranolol and infantile hemangiomas four years later: A systematic review. Pediatr Dermatol 2013; 30: 182-191.
25. Greenberger S, Yuan S, Walsh LA, et al. Rapamycin suppresses self-renewal and vasculogenic potential of stem cells isolated from infantile hemangioma. J Invest Dermatol 2011; 131: 2467-2476.
26. Kaylani S, Theos AJ, Pressey JG,. Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome. Pediatr Dermatol 2013; 30: e194-e197.
27. Ingram DA, Mead LE, Tanaka H, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004; 104: 2752-2760.
28. Melero-Martin JM, De Obaldia ME, Kang SY, et al. Engineering robust and functional vascular networks in vivo with human adult and cord blood-derived progenitor cells. Circ Res 2008; 103: 194-202.
29. Huang L, Critser PJ, Grimes BR, et al. Human umbilical cord blood plasma can replace fetal bovine serum for in vitro expansion of functional human endothelial colony-forming cells. Cytotherapy 2011; 13: 712-721.
30. Reyes M, Dudek A, Jahagirdar B, et al. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 2002; 109: 337-346.
31. Pfaffl MW,. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
32. Boscolo E, Mulliken JB, Bischoff J,. VEGFR-1 mediates endothelial differentiation and formation of blood vessels in a murine model of infantile hemangioma. Am J Pathol 2011; 179: 2266-2277.
33. Medici D, Olsen BR,. Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF. PLoS One 2012; 7: e42913.
34. Lee D, Boscolo E, Durham JT, et al. Propranolol targets contractility of infantile hemangioma-derived pericytes. Br J Dermatol 2014. doi: 10.1111/bjd.13048. [Epub ahead of print]
35. Gu C, Yoshida Y, Livet J, et al. Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. Science 2005; 307: 265-268.
36. Kim J, Oh WJ, Gaiano N, et al. Semaphorin 3E-Plexin-D1 signaling regulates VEGF function in developmental angiogenesis via a feedback mechanism. Genes Dev 2011; 25: 1399-1411.
37. Tal M, Liang Y, Najafi H, et al. Expression and function of GLUT-1 and GLUT-2 glucose transporter isoforms in cells of cultured rat pancreatic islets. J Biol Chem 1992; 267: 17241-17247.
38. Lin RZ, Moreno-Luna R, Li D, et al. Human endothelial colony-forming cells serve as trophic mediators for mesenchymal stem cell engraftment via paracrine signaling. Proc Natl Acad Sci USA 2014; 111: 10137-10142.
39. Yu Y, Flint AF, Mulliken JB, et al. Endothelial progenitor cells in infantile hemangioma. Blood 2004; 103: 1373-1375.
40. Mulliken JB, Glowacki J,. Hemangiomas and vascular malformations in infants and children: A classification based on endothelial characteristics. Plast Reconstr Surg 1982; 69: 412-422.
41. Yuan SM, Jiang HQ, Hong ZJ, et al. [The expression and role of glucose transporter-1 in infantile hemangioma]. Zhonghua Zheng Xing Wai Ke Za Zhi 2007; 23: 90-93.
42. Yanger K, Stanger BZ,. Facultative stem cells in liver and pancreas: Fact and fancy. Dev Dyn 2011; 240: 521-529.
43. Ziv O, Glaser B, Dor Y,. The plastic pancreas. Dev Cell 2013; 26: 3-7.
44. Dudley AC, Khan ZA, Shih SC, et al. Calcification of multipotent prostate tumor endothelium. Cancer Cell 2008; 14: 201-211.
45. Medici D, Shore EM, Lounev VY, et al. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med 2010; 16: 1400-1406.
46. Tao G, Kotick JD, Lincoln J,. Heart valve development, maintenance, and disease: The role of endothelial cells. Curr Top Dev Biol 2012; 100: 203-232.
47. Kovacic JC, Mercader N, Torres M, et al. Epithelial-to-mesenchymal and endothelial-to-mesenchymal transition: From cardiovascular development to disease. Circulation 2012; 125: 1795-1808.
48. Carruthers A, DeZutter J, Ganguly A, et al. Will the original glucose transporter isoform please stand up! Am J Physiol Endocrinol Metab 2009; 297: E836-848.
49. Kleinman ME, Greives MR, Churgin SS, et al. Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arterioscler Thromb Vasc Biol 2007; 27: 2664-2670.
50. Herbert A, Ng H, Jessup W, et al. Hypoxia regulates the production and activity of glucose transporter-1 and indoleamine 2,3-dioxygenase in monocyte-derived endothelial-like cells: Possible relevance to infantile haemangioma pathogenesis. Br J Dermatol 2011; 164: 308-315.
51. Barnes CM, Huang S, Kaipainen A, et al. Evidence by molecular profiling for a placental origin of infantile hemangioma. Proc Natl Acad Sci USA 2005; 102: 19097-19102.
52. Sehgal SN,. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335-340.
53. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135.
54. Phung TL, Ziv K, Dabydeen D, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006; 10: 159-170.
55. Wong A, Hardy KL, Kitajewski AM, et al. Propranolol accelerates adipogenesis in hemangioma stem cells and causes apoptosis of hemangioma endothelial cells. Plast Reconstr Surg 2012; 130: 1012-1021.
56. Stiles J, Amaya C, Pham R, et al. Propranolol treatment of infantile hemangioma endothelial cells: A molecular analysis. Exp Ther Med 2012; 4: 594-604.
57. Ji Y, Li K, Xiao X, et al. Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells. J Pediatr Surg 2012; 47: 2216-2223.